Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 2/20 | 0.48 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | RAF1 | P04049 | 1/20 | 0.35 |
| ▸ | GLRA3 | O75311 | 1/20 | 0.34 |
| ▸ | GLRB | P48167 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | TPMT | P51580 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.30 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1492701 | 0.80 | CES2 (0.42) | DAOGLRA3GLRBHCAR3HCAR2 | |
| SCHEMBL126435 | 0.78 | GLRA3 (0.33) | DAOGLRA3GLRB | |
| SCHEMBL129508 | 0.74 | MAPT (0.33) | DAOGLRA3GLRBKDM4ECYP1A2 | |
| SCHEMBL4363636 | 0.74 | HPGD (0.42) | DAO | |
| SCHEMBL132181 | 0.74 | ESR1 (0.41) | DAOESR1RAF1 | |
| SCHEMBL280067 | 0.73 | ESR1 (0.40) | DAOESR1RAF1MAPK14 | |
| SCHEMBL4426957 | 0.73 | DAO (0.39) | DAOESR1CYP2C9 | |
| SCHEMBL15023276 | 0.71 | SMN1; SMN2 (0.44) | KDM4ECYP1A2CYP2C9 | |
| SCHEMBL7958024 | 0.71 | DAO (0.40) | DAOESR1RAF1KDM4ECYP1A2 | |
| SCHEMBL10835481 | 0.69 | ESR1 (0.41) | DAOESR1RAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8450319-B2 | Pyrrolopyridazinone compound | UBE INDUSTRIES, LTD. (JP) | 2013-05-28 | — | — | US | disclosed |
| EP-1982986-B1 | PYRROLOPYRIDAZINONE COMPOUND AS PDE4 INHIBITOR | UBE INDUSTRIES (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20090036453-A1 | Pyrrolopyridazinone Compound | UBE INDUSTRIES, LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
| EP-1982986-A1 | PYRROLOPYRIDAZINONE COMPOUND | Ube Industries, Ltd. (JP) | 2008-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036453-A1 | Pyrrolopyridazinone Compound | CBR3, CBR1, CYC1 | DAO 388/4885ESR1 2552/4885RAF1 1113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.